Stimulant medication
Summary
- Short-term evidence supports reduced core ADHD symptoms in adults taking stimulant medication.
- Weigh daily-life gains, side effects and personal preference when deciding whether to continue.
- Effects, duration and side effects vary. A clinician should reassess when a formulation is unsuitable.
Ways to apply
Short-term benefits concern core ADHD symptoms
Research-backed
Adult clinical trials show that stimulant medication reduces core symptoms of attention-deficit/hyperactivity disorder (ADHD) at around twelve weeks. Both participants’ self-ratings and clinicians’ assessments support this finding(Ostinelli et al., 2025).
Assessment should track whether target symptoms such as difficulty concentrating improve. Feeling more alert alone is not enough.
Weigh daily-life gains alongside side effects
Research-backed
In adult studies, more people stopped treatment because of side effects in stimulant medication groups than in placebo groups(Gosling et al., 2025).
Follow-up discussions should cover practical improvements in work, study and relationships, whether side effects are tolerable, and whether the person wants to continue medication(NICE, 2018).
One unsuitable formulation does not rule out the whole drug class
Research-backed
The strength and duration of stimulant effects, and side effects, vary between people. Formulations also affect convenience and whether treatment covers the hours needed(NICE, 2018).
Distinguishing “symptoms did not improve” from “it helped, but wore off too soon” at follow-up helps the clinician assess the next steps(NICE, 2018).
Routine checks still matter without discomfort
Research-backed
The National Institute for Health and Care Excellence (NICE) guideline recommends checking adults’ weight, pulse and blood pressure every six months during treatment. Pulse and blood pressure also need checking before and after a clinician changes treatment(NICE, 2018).
Evidence
References (3)
- Meta-analysisComparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysisOstinelli, Schulze, Zangani, Farhat, Tomlinson, Del Giovane, Chamberlain, Philipsen, Young, Cowen, Bilbow, Cipriani, Cortese (2025). The Lancet Psychiatry
- Meta-analysisBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingGosling, Garcia-Argibay, De Prisco, Arrondo, Ayrolles, Antoun, Caparos, Catalán, Ellul, Dobrosavljevic, Farhat, Fico, Eudave, Groenman, Højlund, Jurek, Nourredine, Oliva, Parlatini, Psyllou, Salazar-de-Pablo, Tomlinson, Westwood, Cipriani, Correll, Yon, Larsson, Ostinelli, Shin, Fusar-Poli, Ioannidis, Radua, Solmi, Delorme, Cortese (2025). BMJ
- GuidelineAttention deficit hyperactivity disorder: diagnosis and managementNICE (2018). NICE guideline NG87